DDR1 was expressed at lower levels in lymphoid neoplasm diffuse large B-cell (DLBC), KIRC, acute myeloid leukemia (LAML), pancreatic adenocarcinoma (PAAD), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), and skin cutaneous melanoma (SKCM) but was expressed at higher levels in another 18 tumors (Fig. 1B, Supplementary Table S1). Here, DDR1 is linked to prostate adenocarcinoma.